A Peptide Meets a Radionuclide to Combat a Rare Tumor

Background: Neuroendocrine carcinomas (NECs) are rare malignancies with limited treatment options beyond surgery. Peptide receptor radionuclide therapy (PRRT) is a process by which a somatostatin analog (octreotate) is combined with a chelator (DOTA) and a radionuclide (lutetium-177 [(177)Lu-dotatat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Katharine E., Boudreaux, J. Philip, Thiagarajan, Ramcharan, Marsala, Andrew, Voros, Brianne A., Ramirez, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Division of Ochsner Clinic Foundation 2021
Materias:
Case Reports and Clinical Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442225/
https://www.ncbi.nlm.nih.gov/pubmed/34566515
http://dx.doi.org/10.31486/toj.20.0098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442225/
https://www.ncbi.nlm.nih.gov/pubmed/34566515
http://dx.doi.org/10.31486/toj.20.0098

Ejemplares similares